Work

EE555 Cost-Effectiveness of Etranacogene Dezaparvovec for the Treatment of Hemophilia B

Year: 2023

Type: conference-abstract

Abstract: Etranacogene dezaparvovec (Etranadez) is a new gene therapy for hemophilia B. This study assessed the cost-effectiveness of Etranadez compared with Factor IX (FIX), in hemophilia B patients without inhibitors eligible for prophylaxis. A special consideration in this assessment was employing a cost savings cap for the new therapy as the existing treatments come at exceptionally high costs.

Source: Value in Health

DOI: 10.1016/j.jval.2023.03.2533

Authors: J. Sarker, A. Moradi, M. Whittington, J.A. Tice, B. Herce-Hagiwara, S.M. Fahim, J. Chu, F.O. Agboola, S. Pearson, D.M. Rind, S. Walton

Institutions: University of Illinois Chicago, Institute for Clinical and Economic Review, University of California, San Francisco

Language: English

Topic: Hemophilia Treatment and Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,200

OpenAlex ID: W4380150171

Cites:

Cited by: 1

Related to: 10